BioSyent Releases Third Quarter Results; Record Quarterly

New Post Public Reply Private Reply Replies (0) Message Board
Rawnoc

BioSyent Releases Third Quarter Results; Record Quarterly Sales and Profit: Sales Up 60%, Profit Up 79%

TORONTO, ONTARIO--(Marketwire - Nov 15, 2012) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today released a summary of its Third Quarter (Q3) 2012 financial results.

- Q3 2012 Sales of $1,575,598 sets an all time quarterly record and grew by 60% over Q3 2011
- Q3 2012 Pharmaceutical Sales of $1,180,718 grew by 95% vs. $604,523 in Q3 2011
- Sales for the nine months ended September 30, 2012 of $3,696,201 grew by 76% over the prior year period
- Total Comprehensive Income for Q3, 2012 of $423,015 hit an all time quarterly record and was higher than that of 2011 by 79%
- Total Comprehensive Income for the nine months ended September 30, 2012 of $1,034,828 grew by 196% over the corresponding prior year period
- Cash generation of $878,751 for the nine months ended September 30, 2012 increased by 147% over the corresponding period in 2011
- Q3 2012 basic earnings per share (EPS) were $0.03
- Cumulative Basic EPS over the last 4 consecutive quarters is $0.09

Total Sales for Q3 2012 hit a new quarter record and were $1,575,598 or 60% higher compared to $983,857 in the corresponding prior year period and 30% higher than the immediately preceding quarter (Q2 2012) which had sales of $1,216,115. For the nine months ended September 30, 2012, the Total Sales of $3,696,201 were 76% higher than the corresponding prior year period.

Pharmaceutical Sales were $1,180,718 in Q3 2012, or 95% higher than the corresponding prior year period sales which were $604,523. For the nine months ended September 30, 2012, Pharmaceutical Sales of $2,996,115 were 115% higher than $1,392,334 in the corresponding prior year period.

The Company earned Total Comprehensive Income of $423,015 in Q3 2012, which was 79% higher than the Total Comprehensive Income of $235,999 in Q3 2011. For the nine months ended September 30, 2012, the Total Comprehensive Income of $1,034,828 was 196% higher than $349,452 in the corresponding prior year period.

Working capital has increased by 94% from $1,128,065 as at December 31, 2011 to $2,184,891 as at September 30, 2012. Cash and cash equivalents on September 30, 2012 were 89% of working capital compared to 94% as at December 31, 2011. Total Cash generation for the nine months ended September 30, 2012 of $878,751 increased by 147% over the corresponding prior year period.

The Company''s subsidiary BioSyent Pharma Inc. is completing preparations for a Q1 2013 launch of FeraMAX® Powder which was approved by Health Canada earlier this year.

The Financial Statements and Management''s Discussion & Analysis will be posted on www.sedar.com on November 15, 2012.

As at the date of this press release the Company had 12,921,195 shares issued and outstanding.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. The Company is focused on medications that occupy a niche in the market, that are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to, it.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company''s legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Contact:
BioSyent Inc.
Rene C. Goehrum
President and CEO
www.biosyent.com

Biosyent Inc (BIOYF) Stock Research Links

BIOYF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cumberland Pharmaceuticals Eyes NDA for Ifetroban in DMD

Updated Category News Views 72

Rolling the Dice with Ifetroban There's a buzz in the air around Cumberland Pharmaceuticals as they gear up to tackle one of medicine's stubborn giants, Duchenne muscular dystrophy (DMD). They plan to file a New Drug Application (NDA) with the FDA for ifetroban, aiming to treat the cardiomyopathy plaguing many DMD sufferers. Folks who’ve watched Cumberland (NASDAQ:CPIX)...

Continue Reading
AI Deepfakes Met Their Match: IC-Corp's New Patent

Updated Category News Views 146

The Deepfake Fraud Reality Slap You know, in a world where you can't trust your own eyes on a video call, trust gets a bit sketchy, right? Imagine this scenario—an unsuspecting finance employee, surrounded by familiar faces and voices, only to wind up sending $25.6 million to fraudsters who weren't even real. A chilling real-world example from January 2024, courtesy of...

Continue Reading
Investor Scrutiny Intensifies Over M&A Deals at SGRY, RRC, EQT

Updated Category News Views 118

When Insiders Seem to Benefit More Ah, mergers and acquisitions—it's the oldest tango in the business world. But today, we've got some footwork that might trip up the small fry. Halper Sadeh LLC, the investor rights bulldogs, are sniffing around Surgery Partners, Range Resources, and EQT. Their quest? To uncover whether the big dogs are playing unfairly with...

Continue Reading
Mission Bancorp Hits Record Earnings, Extends Buyback

Updated Category News Views 60

Record-Breaking Quarter Amid Challenging Times When Mission Bancorp's earnings hit the tape today, the numbers were enough to catch anyone's eye—$9.2 million in net income for Q3 2026, a 6% increase from last year. That's not small potatoes, especially considering the economic fog we're navigating through. AJ Antongiovanni, holding the reins as CEO, credits the bank's...

Continue Reading
Columbia Distributing Expands to Alaska: A Growth Move

Updated Category News Views 55

Alaska's Entry: Columbia's New Frontier When Columbia Distributing dives into a new territory, you know they're serious about growth. This latest move sees them planting their flag in Alaska, finally completing a strategic vision that's been brewing for a while. Four-State Strategy Comes to Fruition The transaction with Republic National Distributing Company (RNDC) is no...

Continue Reading
ADSQUIRE Dominates 2026 with Jaw-Dropping ROI and Award

Updated Category News Views 58

ADSQUIRE's Phenomenal ROI Grabs Industry Spotlight Just when you think the PPC world has seen it all, ADSQUIRE steps in and flips the script. With a jaw-dropping 8,000% return on investment (ROI) from a mere $4,000 ad spend in just one month, they've taken the PPC Agency of the Year title at the 2026 Search Engine Land Awards. For a Philadelphia-based agency focused on...

Continue Reading
Duke Energy's Battle Against Energy Vampires Heats Up

Updated Category News Views 248

Unplugging Hidden Electricity Drains Ever wonder why your electric bill has been sneakily creeping up? You might think it's just the AC running full blast or lights left on, but surprise, surprise—there’s a whole army of “energy vampires” quietly sucking the juice out of your home. Duke Energy Florida is drawing attention to this sneaky leak, especially around...

Continue Reading
Brennan Takes a Swing: Barrasso Endorsement in Hand

Updated Category News Views 44

Brennan Shakes Up Wyoming Politics You don’t need a crystal ball to see the chess game unfolding in Wyoming's political landscape. Shannon Brennan's bid for the House seat in Teton County's District 23 got a heavy artillery boost today. She’s landed the endorsement of Senator John Barrasso, none other than the Senate Majority Whip and a formidable player in the Senate...

Continue Reading
ROKAE Hits 10,000 Delivery Mark for Robotic Arms

Updated Category News Views 167

ROKAE's Big 10K: A Milestone Worth Noting Alright, if you've been around the block as long as I have, you know the robotics game isn't just about making cool gadgets—it's about hitting those serious deployment numbers. ROKAE Robotics just rolled its 10,000th humanoid force-controlled arm off the line in Shandong, and this ain't just another notch on their belt. This...

Continue Reading
Revamp Preschool Questions for Richer Conversations

Updated Category News Views 81

Preschoolers, those tiny agents of chaos, come home with stories that you'd need a magnifying glass to find. Ask 'em "How was school?" and you're met with blank stares or a one-liner. Tami Nix of Archway Academy has been at this game for over 40 years, and she's got a trick or six up her sleeve. Ditch the Generic: Get Specific Yep, those generic questions are about as...

Continue Reading

Top 5 Most Recently Viewed Articles

Beneq Unveils Advanced Beneq Transform® XP for ALD Technology

Updated Category News Views 192

Beneq Introduces Next-Gen Beneq Transform® XP Beneq has recently announced the Beneq Transform® XP, a sophisticated second-generation atomic layer deposition (ALD) platform designed to address the evolving demands of Wide Bandgap (WBG) power and RF device manufacturing. This innovative system is poised to redefine atomic control and optimization in ALD processes....

Continue Reading
Capital Square Achieves Remarkable 152% Return for Investors

Updated Category News Views 115

Exceptional Returns Delivered by Capital Square In a notable transaction recently executed by Capital Square, investors have experienced a remarkable total return of 152%. The real estate investment firm, acknowledged for its prowess in tax-advantaged real estate investments, completed a successful UPREIT transaction involving the Mayton Transfer Lofts, a multifamily...

Continue Reading
Transforming Third-Party Risk Management in Cybersecurity

Updated Category News Views 243

Understanding the Challenges of Third-Party Risk Management In an era where cyber threats evolve rapidly, traditional approaches to vulnerability management are becoming increasingly inadequate. With a staggering increase of 38% year-over-year in published Common Vulnerabilities and Exposures (CVEs), organizations face significant challenges in navigating third-party risk...

Continue Reading
Newton Golf's Fast Motion Shaft: Revolutionizing Golf Performance

Updated Category News Views 355

Introducing the Newton Fast Motion Shaft NEWTON GOLF Company (NASDAQ: NWTG), a leader in innovative golf technology, has unveiled its latest creation—the Fast Motion shaft. This lightweight shaft is meticulously engineered for golfers seeking to maximize their driving distance and control without sacrificing performance. With a retail price of $325, the Newton Fast...

Continue Reading
LG Energy Solution Faces Challenges Amid Slowing EV Demand

Updated Category News Views 177

LG Energy Solution Reports Challenging Financial Results LG Energy Solution, a prominent player in the battery manufacturing sector, has recently announced a significant shift in its financial outlook. After three consecutive years of profitability, the company faced its first quarterly loss, raising concerns among investors and industry stakeholders alike. Decline in...

Continue Reading